Tactile Systems expands lymphedema portfolio with LymphaTech

MINNEAPOLIS – Tactile Systems Technology has acquired LymphaTech for an upfront cash payment at closing of $6.8 million, plus potential additional consideration that is contingent upon the achievement of future milestones. 

The acquisition will expand Tactile Medical’s lymphedema portfolio with new solutions that enable more accurate and efficient disease identification and progression, while broadening the company’s research and development capabilities and strengthening its market leadership position in conditions associated with lymphatic dysfunction. 

“This acquisition is a milestone in Tactile’s evolution from a product-based company to a comprehensive, integrated solutions leader for lymphatic dysfunction,” said Sheri Dodd, CEO of Tactile Medical. “By bringing together Tactile and LymphaTech, we become uniquely positioned to support patients and clinicians from early disease intervention to innovative connected therapies with long-term support and monitoring alongside our Kylee patient engagement application.” 

LymphaTech’s primary technology is a hand-held, clinically validated solution that uses proprietary algorithms and mobile scanning to deliver highly accurate fluid volume and precise circumference measurements, two critical elements in identifying lymphedema and informing the appropriate therapy options. The platform immediately generates a clinical grade 3D model of the body and limbs, replacing traditional manual measurement methods that are time consuming and highly variable. 

In connection with the transaction, LymphaTech co-founders Mike Weiler and Nate Frank have joined Tactile Medical to drive commercial adoption of the LymphaTech platform and support ongoing research activities.